Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia

Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news